EDIT stock forecast
Our latest prediction for Editas Medicine, Inc.'s stock price was made on the Nov. 1, 2018 when the stock price was at 27.46$.
In the short term (2weeks), EDIT's stock price should outperform the market by 0.60%. During that period the price should oscillate between -8.27% and +10.06%.
In the medium term (3months), EDIT's stock price should outperform the market by 1.51%. During that period the price should oscillate between -17.53% and +27.05%.
Get email alertsCreate a solid portfolio with EDIT
About Editas Medicine, Inc.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
At the moment the company generates 21M USD in revenues.
On its last earning announcement, the company reported a loss of -2.68$ per share.
The book value per share is 4.84$
Three months stock forecastNov. 1, 2018
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21M | - | -141M | -686.40% | -134M | -2.68 | - | - | 50M | 4.84 | -41M | -6M | -47M |